DMPK (drug metabolism and pharmacokinetics) studies are used for the rational selection of suitable drug candidates in the context of the development of a (bio)pharmaceutical drug. Due to many years of expertise, Axolabs can offer its customers DMPK activities in the following areas: 

• Identification of oligonucleotide metabolites by LC/MS
• Characterization of nucleosides and nucleotides
• Analysis of oligonucleotide-protein interactions like plasmaproteinbinding
• PK and biodistribution analyses of oligonucleotides and mRNAs
• Pharmacokinetic evaluation of measurement data using NCA (Non-Compartmental Analyses).

  • Evaluation of concentration-time data of preclinical and clinical studies (plasma and urine) determined in-house as NCA (Non-Compartmental Analyses) using the Phoenix WinNonlin® software. The analysis delivers meaningful graphs as well as important parameters for planning further studies, such as half-life, maximum exposure (c_max), time of maximum exposure (t_max), total exposure (AUC; area under the curve), volume of distribution (V_z) and clearance (Cl).